Stifel bumped up its price target for Okta, Inc. (NASDAQ:OKTA) to $130 from $120. The firm also reiterated a Buy rating on ...

On May 24, analysts at Stifel reaffirmed their Buy rating and price target of $48 for Bicara Therapeutics Inc. (NASDAQ:BCAX).

and on Friday a three-person arbitration panel ruled Stifel Nicolaus & Co. Inc. pay $7 million in legal costs of advisors who left the firm in 2023 and then were sued by the firm. It’s the ...

The St. Louis-based financial services giant has inked what officials called an "unprecedented" extension of its sponsorship ...

The competing legal strategies appear contrary to Stifel’s public statements about defending its structured notes’ tactics.

On Friday, Stifel analysts adjusted their financial outlook for Abeona Therapeutics (NASDAQ: ABEO), reducing the price target to $20.00 from the previous $21.00.Despite this change, the firm has ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Stifel Fine Arts Center hosted an open house to introduce this year’s Artist-in-Residence. It’s part of a program where the Center selects three artists from around the country and invites them to use ...

Stifel analyst Tore Svanberg raised the firm’s price target on Microchip (MCHP) to $70 from $60 and keeps a Buy rating on the shares after fiscal Q4 results were higher than estimates, the ...

In addition to Stifel Nicolaus, Illumina also received a Buy from RBC Capital’s Conor McNamara in a report issued today. However, on the same day, Barclays maintained a Sell rating on Illumina ...